Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.41 +0.02 (+0.34%)
At close: Aug 20, 2026 · 10:51 AM UTC

Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Interest & Investment Income came in at $35919.0 in Q4 2025, up 119630.0% YoY from N/an in Q4 2024, and down 36.34% on a QoQ basis from $56426.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Interest & Investment Income data on file, last reported at $35919.0 in Q4 2025.

  • Quarterly Interest & Investment Income rose 119630.0% year-over-year to $35919.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $107595.0 (up 3710.02% YoY) and the FY2025 annual result came in at $107595.0, up 3710.02% from the prior year.
  • Interest & Investment Income retreated to $35919.0 in Q4 2025, from $56426.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $56426.0 in Q3 2025 to a low of $3.0 in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Haleon 43.81 Bn 42.84 Bn - -
2 Teva Pharmaceutical Industries 43.29 Bn 39.63 Bn 2.15 Bn -
3 Zoetis 31.59 Bn 29.91 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.67 Bn 22.88 Bn 5.10 Bn 154.39 Mn
5 United Therapeutics 22.24 Bn 19.58 Bn 683.80 Mn 31.50 Mn
6 Viatris 18.79 Bn 17.91 Bn 1.46 Bn -
7 Neurocrine Biosciences 15.71 Bn 15.32 Bn 935.80 Mn 12.40 Mn
8 Elanco Animal Health 12.09 Bn 11.56 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.11 Bn 9.95 Bn - -
10 Apimeds Pharmaceuticals US 7.55 Mn 7.55 Mn - 21,764.00

Historic Data

Download Data
DateValue
Dec 31, 2025 35,919.00
Sep 30, 2025 56,426.00
Jun 30, 2025 15,247.00
Mar 31, 2025 3.00
Dec 31, 2024 30.00
Sep 30, 2024 116.00
Jun 30, 2024 517.00
Mar 31, 2024 2,161.00